Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Hemab Therapeutics Holdings, Inc. (COAG) AI Forecast

Our AI analyzed Hemab Therapeutics Holdings, Inc.. Create a free account and follow it to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$COAG Neutral Signal Full forecast available
Sign Up Free

Hemab Therapeutics Holdings, Inc. (COAG) Stock Forecast Sept. 5, 2026

Hemab Therapeutics Holdings, Inc. (COAG) AI Stock Price Forecast & Investment Analysis

Hemab Therapeutics Holdings, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Hemab Therapeutics Holdings, Inc. (COAG) - Comprehensive Stock Analysis & Investment Research

Deep dive into Hemab Therapeutics Holdings, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 5, 2026, 2:13 p.m. (UTC)

Hemab Therapeutics Holdings, Inc. Investment Summary

When evaluating whether Hemab Therapeutics Holdings, Inc. (COAG) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Hemab Therapeutics Holdings, Inc. (COAG) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $2 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.

Financial Performance Analysis

Our comprehensive financial analysis covers Hemab Therapeutics Holdings, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Hemab Therapeutics Holdings, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Hemab Therapeutics Holdings, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Hemab Therapeutics Holdings, Inc.

Sign Up Free
Corporate Identity

Hemab Therapeutics Holdings, Inc. (Stock Symbol: COAG) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Hemab Therapeutics Holdings, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Hemab Therapeutics Holdings, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Hemab Therapeutics Holdings, Inc....

Unlock Full Company Profile

Get complete details about Hemab Therapeutics Holdings, Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Hemab Therapeutics Holdings, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Hemab Therapeutics Holdings, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Hemab Therapeutics Holdings, Inc....

Unlock Financial Analysis

Get complete financial metrics for Hemab Therapeutics Holdings, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Hemab Therapeutics Holdings, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Hemab Therapeutics Holdings, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.

Industry Competitive Landscape

Hemab Therapeutics Holdings, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-89 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Financial Strength & Leverage

Current ratio of 35.85 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Hemab Therapeutics Holdings, Inc. (COAG) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Hemab Therapeutics Holdings, Inc. stock analysis.

Deep dive into Hemab Therapeutics Holdings, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Hemab Therapeutics Holdings, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Hemab Therapeutics Holdings, Inc.:

P/B Ratio 4.56x
Market Cap $2.07B
Book Value/Share $9.72
FCF/Share $-1.90
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Hemab Therapeutics Holdings, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Hemab Therapeutics Holdings, Inc.:

Understanding Financial Health Metrics

What these metrics mean: These ratios assess Hemab Therapeutics Holdings, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Hemab Therapeutics Holdings, Inc.: A current ratio of 35.85 indicates strong liquidity.

Current Ratio 35.85x
D/E Ratio 0.03x
Financial Leverage 1.03x
Working Capital $451M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Hemab Therapeutics Holdings, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Hemab Therapeutics Holdings, Inc.: Free cash flow of $-89M indicates cash challenges that need attention.

Free Cash Flow -$89M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Hemab Therapeutics Holdings, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Hemab Therapeutics Holdings, Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Hemab Therapeutics Holdings, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Hemab Therapeutics Holdings, Inc.:

Income Statement
Balance Sheet Highlights (% Of Assets)
Total Current Assets 464%
Cash & Short-term Investments 237%
Total Liabilities 14%
Short-term Debt 7%
Dividend & Shareholder Information
Shares Outstanding 47M

Latest Hemab Therapeutics Holdings, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Hemab Therapeutics Holdings, Inc. (COAG) stock price and investment outlook.

📰 Loading...

Where COAG sits on the market map

Explore the map →

Hemab Therapeutics Holdings, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Hemab Therapeutics Holdings, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS ██% $230M x 4.0x
ABPO ██% $1M x x
ACOG ██% $207M x 3.9x
ADAPY ██% $8M x x
ADMA ██% $2.17B 12.8x 5.3x
ADPT ██% $3.86B x 27.0x
AGEN ██% $351M 3.8x x
AGTX ██% $800K x x
AIM ██% $7M x 0.9x
ALEC ██% $252M x x
ALGS ██% $39M x 1.2x
ALLO ██% $680M x 1.6x
ALVO ██% $1.90B x x
AMGN ██% $236.37B 27.0x 20.2x
APGE ██% $10.18B x x
APTN ██% $57M x x
APTOF ██% $4M x x
ARGX ██% $65.31B x x
ARMP ██% $217M x x
ARTV ██% $543M x 1.6x
ATRA ██% $92M x x
ATYR ██% $49M x 1.0x
AURA ██% $784M x 2.5x
AUTL ██% $596M x 8.0x
AVXL ██% $266M x 2.1x
BCAB ██% $2M x x
BCDA ██% $16M x 6.0x
BCLI ██% $12M x x
BCRX ██% $2.54B x x
BDTX ██% $122M x 1.3x
BEAM ██% $3.06B x 2.9x
BIIB ██% $32.98B 24.0x 1.8x
BKHA ██% $50M 97.5x x
BNTX ██% $26.06B x x
CABA ██% $588M x 2.8x
CADL ██% $973M x 7.7x
CCCC ██% $462M x 1.9x
CELZ ██% $7M x 0.8x
CERO ██% $790K x x
CGEM ██% $1.42B x 4.4x
CGEN ██% $245M 3.5x 2.4x
CGON ██% $6.59B x 6.4x
CGTX ██% $98M x 3.0x
CHRS ██% $219M x 3.6x
CLDI ██% $3M x 1.1x
CLLS ██% $334M x x
CMPX ██% $427M x 2.6x
COAG ██% $2.07B x 4.6x
CPMV ██% $440K x x
CRDF ██% $84M x 3.2x
CRDL ██% $252M x x
CRIS ██% $3M x 0.7x
CRSP ██% $5.46B x 3.1x
CSBR ██% $73M x 18.6x
CVM ██% $28M x 2.6x
DBVT ██% $861M x 5.4x
DNA ██% $434M x 1.0x
DNLI ██% $3.64B x 4.4x
DTIL ██% $194M x 4.3x
DYAI ██% $20M x x
EDIT ██% $470M x 4.5x
EIKN ██% $588M x 1.3x
ELUT ██% $36M 0.7x 2.3x
ENGN ██% $123M x 0.5x
ENTX ██% $519M x 71.5x
ENZN ██% $67M x 0.4x
ESLA ██% $31M x x
EVAX ██% $28M x x
EXEL ██% $14.69B 17.1x 8.0x
EXOZ ██% $64M x 17.4x
FATE ██% $289M x 1.9x
FDMT ██% $827M x 2.0x
FENC ██% $434M x 10.2x
GILD ██% $185.67B x 15.7x
GLUE ██% $1.18B x 2.4x
GNTA ██% $48M x 3.9x
GPLB ██% $180K x x
GRML ██% $15M x 0.3x
HALO ██% $12.57B 30.4x 87.5x
HUMA ██% $166M x 5.3x
IBRX ██% $8.51B x x
IKT ██% $330M x 2.2x
IMA ██% $55M x 0.4x
IMCR ██% $1.92B x 4.6x
IMTX ██% $1.46B x x
IMVT ██% $8.10B x 11.0x
INAB ██% $12M x 0.6x
INKT ██% $58M x x
INMB ██% $67M x 3.3x
INTS ██% $12M x 1.4x
IOVA ██% $3.98B x 5.4x
IPSC ██% $381M x 1.6x
IVVD ██% $237M x 1.3x
JATT ██% $95M x 0.5x
JSPR ██% $24M x 16.7x
KLRS ██% $93M x 1.6x
KOD ██% $2.22B x 36.4x
KRYS ██% $10.60B 43.9x 7.8x
KYMR ██% $9.82B x 6.5x
KYTX ██% $508M x 3.1x
LCTX ██% $273M x 4.5x
LENZ ██% $187M x 0.9x
LIFE ██% $3.91B x 80.1x
LIMN ██% $5M x 16.6x
LONA ██% $71M x 2.1x
LXEO ██% $384M x 1.6x
MAZE ██% $1.48B x 3.3x
MESO ██% $2.25B x x
MGTX ██% $1.31B 16.6x 6.1x
MGX ██% $44M x 0.4x
MOLN ██% $176M x x
MRNA ██% $58.07B x 8.6x
NBIX ██% $15.81B 22.4x 4.3x
NMRA ██% $256M x 5.7x
NVAX ██% $1.68B x x
OCGN ██% $448M x x
OTLK ██% $162M x x
PALI ██% $363M x 3.0x
PASG ██% $15M x 3.4x
PCVX ██% $8.86B x 3.2x
PHGE ██% $4M x 0.4x
PLUR ██% $18M x x
PLX ██% $214M 11.3x 3.0x
PMCB ██% $5M x 0.2x
PRME ██% $649M x 16.3x
PROK ██% $802M x x
PTHS ██% $91M x x
QGEN ██% $9.39B x 2.5x
QNCX ██% $32M x x
REPL ██% $1.42B x 13.4x
RGEN ██% $9.46B 227.7x 4.5x
RGNX ██% $590M x 8.2x
RLAY ██% $4.05B x 4.5x
RVMD ██% $45.00B x 17.3x
RXRX ██% $1.94B x 2.1x
SABS ██% $313M x 1.5x
SANA ██% $1.15B x 7.5x
SCLX ██% $38M x x
SCNI ██% $1M x 0.2x
SGMO ██% $29M x x
SGMOQ ██% $62M x x
SLDB ██% $1.08B x 2.9x
SLXN ██% $2M x 46.8x
SNTI ██% $10M x x
SRRK ██% $6.73B x 26.5x
SRZN ██% $268M x x
STRO ██% $333M x x
TARA ██% $225M x 1.4x
TARS ██% $3.93B x 11.3x
TCRX ██% $48M x 0.7x
TECH ██% $11.31B 62.2x 5.4x
TECX ██% $591M x 2.6x
TIL ██% $52M x 0.5x
TNYA ██% $155M x 2.2x
TSHA ██% $1.79B x 4.6x
TVGN ██% $47M x x
TWST ██% $7.85B x 17.6x
VACH ██% $541M 80.4x x
VALN ██% $621M x x
VCEL ██% $2.07B 85.4x 5.6x
VIR ██% $1.92B x 2.0x
VISK ██% $69M x 0.4x
VIVS ██% $4M x x
VOR ██% $1.28B 2.0x x
VXRT ██% $121M 3.2x 1.5x
VYGR ██% $211M x 1.4x
WINT ██% $10K x x
XFOR ██% $388M x 2.5x
ZEOX ██% $9M x 13.1x
ZIVO ██% $14M x x
ZURA ██% $582M x 3.0x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Hemab Therapeutics Holdings, Inc. Stock Forecast

How accurate are Hemab Therapeutics Holdings, Inc. stock predictions?

Our AI model shows a 8% Spearman correlation coefficient for COAG predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Hemab Therapeutics Holdings, Inc. stock price forecasts?

Our analysis considers Hemab Therapeutics Holdings, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Hemab Therapeutics Holdings, Inc. a good investment in 2026?

Based on our AI analysis, Hemab Therapeutics Holdings, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Hemab Therapeutics Holdings, Inc. forecasts updated?

Hemab Therapeutics Holdings, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Hemab Therapeutics Holdings, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...